Core Viewpoint - Vericel Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in therapies for sports medicine and severe burn care [1]. Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care, combining biological innovations with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [2]. - The company markets three primary products in the United States: - MACI® is an autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [2]. - Epicel® is a permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [2]. - Vericel holds an exclusive license for NexoBrid®, a biological orphan product for eschar removal in burn patients [2].

Core Insights - MediWound Ltd. announced a peer-reviewed post hoc analysis of its Phase II ChronEx clinical trial, demonstrating the efficacy and safety of EscharEx® compared to SANTYL® for treating venous leg ulcers [1][2] Company Overview - MediWound Ltd. is a global biotechnology company focused on developing enzymatic therapies for non-surgical tissue repair, with FDA-approved NexoBrid® for thermal burns and EscharEx® in advanced clinical development for chronic wounds [6][5] Clinical Trial Findings - The post hoc analysis published in Wounds compared outcomes of 46 patients treated with EscharEx to 8 patients treated with SANTYL, showing significant advantages for EscharEx in debridement and wound bed preparation [2][4] - Complete debridement at 2 weeks was achieved in 63% of EscharEx patients versus 0% in the SANTYL group (p = 0.001) [7] - Median time to debridement was 9 days for EscharEx compared to not achieved for SANTYL (p = 0.023) [7] - Wound bed preparation was achieved by 50% of EscharEx patients in 2 weeks versus 0% with SANTYL (p = 0.015) [7] - Over 12 weeks, 78% of EscharEx patients achieved wound bed preparation compared to 38% with SANTYL (p = 0.03) [7] Safety and Efficacy - Adverse event rates were similar between both treatment groups, but deep wound infection occurred in 11% of EscharEx patients compared to 38% in the SANTYL group [7] - Mean time to wound closure was 48 days for EscharEx versus 76 days for SANTYL among those who achieved closure (p = 0.05) [7] Market Potential - EscharEx targets a substantial global market opportunity, with ongoing Phase III studies in venous leg ulcers and preparations for studies in diabetic foot ulcers [5][6]